Furthermore, investigating the role of STC2 in other subtypes of breast cancer, including triple-negative and HER2-positive cancers, could determine whether the findings are broadly applicable across breast cancer subtypes or specific to luminal A and ER-positive patients. This evidence concerns the gene ESR1 and breast carcinoma.